Methods for control of an infective disease with a vaccine
AssigneeRussellville Cardiology Consultants, P.A.
InventorDai Yuan Wang
Life of this patent
Estimating the term…
Abstract
The COVID-19 pandemic has led to a worldwide health crisis and devastating economic and social issues. The present invention provides a method enhancing the effectiveness of the vaccines currently used for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which comprises three incremental doses of a vaccine to elicit an enhanced immune response against in a subject. The first dose, second dose, and final dose are administered in the amount of 10-25%, 45-55%, and about 100% of the vaccine's full-strength dose, respectively.
Claims13
A method for enhancing an immune response to a coronavirus in a subject, comprising:
- (1) administering to the subject a first dose of a coronavirus vaccine in the amount of 10-25% of the vaccine's full-strength dose on Day 1 of an administering schedule;
- (2) administering to the subject a second dose of the coronavirus vaccine in the amount of 45-55% of the vaccine's full-strength between Day 4-22 of the administering schedule;
- and
- (3) administering to said subject a final dose of the coronavirus vaccine in the amount of 80-100% of said vaccine's full-strength on the last day of the administering schedule;
- wherein the immune response produced in the subject is stronger than, and/or lasts longer than the immune response produced in the subject if the full-strength dose is given two or three times over the same length of time of the administering schedule.
A method for enhancing an immune response to SARS-COV-2 in a subject, comprising:
- (1) administering to the subject a first dose of a SARS-COV-2 vaccine in the amount of 10% of the vaccine's full-strength dose on Day 1 of an administering schedule;
- (2) administering to the subject a second dose of the SARS-COV-2 vaccine in the amount of 50% of the vaccine's full-strength on about Day 14 of the administering schedule;
- and
- (3) administering to said subject a final dose of the SARS-COV-2 vaccine in the amount of 100% of said vaccine's full-strength on the Day 28 of the administering schedule;
- wherein the immune response produced in the subject is stronger than, and/or lasts longer than the immune response produced in the subject if the full-strength dose is given two or three times over the same length of time of the administering schedule;
- wherein the SARS-COV-2 vaccine is an inactivated virus vaccine.
Dependencies are inferred from the claim text.